| Control group | Intervention group | Modelb | P- value | Effect size | ||
---|---|---|---|---|---|---|---|
n = 171 | n = 141 | ||||||
 | Mean | (SD) | Mean | (SD) | Adjusted mean difference (95 % CI) | P | d |
FES-IAB | Â | Â | Â | Â | Â | Â | Â |
 Baseline | 29.09 | (9.3) | 29.06 | (9.7) | - | - | - |
 5-month follow-up | 28.74 | (9.2) | 26.17 | (9.6) | −2.38 (−∞ − −1.12) | .001 | .27 |
 12-month follow-up | 29.36 | (10.3) | 26.37 | (10.4) | −2.67 (−∞ – −1.37) | .001 | .29 |
GARS | Â | Â | Â | Â | Â | Â | Â |
 Baseline | 33.73 | (9.3) | 34.11 | (9.4) | - | - | - |
 5-month follow-up | 33.32 | (8.9) | 32.42 | (8.9) | −1.10 (−∞ – −0.07) | .040 | .10 |
 12-month follow-up | 34.04 | (9.3) | 32.41 | (9.4) | −1.81 (−∞ – −0.77) | .002 | .17 |
GARS ADL | Â | Â | Â | Â | Â | Â | Â |
 Baseline | 18.70 | (4.9) | 18.47 | (4.9) | - | - | - |
 5-month follow-up | 18.28 | (4.5) | 17.37 | (4.7) | −0.62 (−∞ – −0.04) | .039 | .20 |
 12-month follow-up | 18.69 | (4.8) | 17.60 | (4.9) | −0.83 (−∞ – −0.24) | .011 | .22 |
GARS IADL | Â | Â | Â | Â | Â | Â | Â |
 Baseline | 15.03 | (4.9) | 15.64 | (5.1) | - | - | - |
 5-month follow-up | 15.05 | (5.1) | 15.04 | (4.8) | −0.52 (−∞ – 0.08) | .075 | - |
 12-month follow-up | 15.35 | (5.1) | 14.82 | (5.0) | −1.01 (−∞ – −0.41) | .003 | .10 |